Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
688192.SS
Strong SellDizal (Jiangsu) Pharmaceutical Co., Ltd. · Healthcare · China · $4.2B · Avg Vol: $96M/d
COMPANY DESCRIPTION
Dizal (Jiangsu) Pharmaceutical Co., Ltd. is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative oncology and autoimmune therapies. The company's competitive moat is built on its strong translational medicine platform and a pipeline of highly differentiated small-molecule targeted therapies, such as sunvozertinib. It is an R&D-driven biotechnology innovator holding global development rights for its key pipeline assets.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 91.3M | 359.9M | 801.1M | 196.2% | 895.6M | 1.2B | 1.8B | 48.5% |
| EPS (CNY) | -1.82 | -2.72 | -2.04 | -1.71 | — | -1.29 | — | — | — |
| Shares | 407.2M | 408.2M | 417.6M | 461.2M | +13.3% | 465.2M | — | — | — |
| Debt | 85.3M | 410.4M | 1.2B | 1.2B | 144.1% | 1.4B | — | — | — |
| Equity | 1.8B | 848.6M | 193.8M | 1.3B | -9.7% | — | — | — | — |
| Op CF | -603.4M | -967.9M | -650.5M | -588.3M | — | -658.3M | — | — | — |
| Inv CF | 384.6M | 611.2M | -38.1M | -1.2B | — | — | — | — | — |
| Fin CF | -33.3M | 308.2M | 867.0M | 1.8B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688192.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 688192.SS | Dizal (Jiangsu) Pharmaceutical Co., Ltd.(you) | $4.2B | 13 | Strong Sell |
| 300436.SZ | Fujian Cosunter Pharmaceutical Co., Ltd. | $2.2B | 13 | Strong Sell |
| 688185.SS | CanSino Biologics Inc. | $2.6B | 19 | Strong Sell |
| 000766.SZ | Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd | $2.3B | 8 | Strong Sell |
| 600521.SS | Zhejiang Huahai Pharmaceutical Co., Ltd. | $3.7B | 32 | Sell |
| 688321.SS | Shenzhen Chipscreen Biosciences Co., Ltd. | $1.7B | 17 | Strong Sell |
| 002294.SZ | Shenzhen Salubris Pharmaceuticals Co., Ltd. | $5.3B | 30 | Sell |
| 000534.SZ | Wedge Industrial Co.,Ltd. | $1.8B | 20 | Strong Sell |
| 000661.SZ | Changchun High-Tech Industry (Group) Co., Ltd. | $4.8B | 34 | Sell |
| 600518.SS | Kangmei Pharmaceutical Co., Ltd. | $2.8B | 30 | Sell |
Peer medians: ROE 4.5% · P/E 29.0x · Gross margin 52.6%